Ms. Samira Sakhia reports

KNIGHT AMENDS NORMAL COURSE ISSUER BID

Knight Therapeutics Inc. has received acceptance by the Toronto Stock Exchange to amend the company's previously announced notice of intention to make a normal course issuer bid (NCIB) to increase the maximum number of common shares that it intends to repurchase for cancellation during the 12-month period ending Aug. 21, 2026, from three million common shares to 6,190,493 common shares, representing approximately 10 per cent of the public float of common shares as at Aug. 8, 2025. All other terms and conditions of the NCIB remain unchanged.

The common shares may be purchased for cancellation through the facilities of the TSX or through alternative Canadian trading systems at times and in numbers to be determined by the company. During the period from Aug. 22, 2025, to March 19, 2026, inclusively, the company purchased 1,767,300 common shares through the facilities of the TSX and alternative Canadian trading systems at a weighted average price per share of $6.08.

Knight has amended its automatic share purchase plan (ASPP) with its broker to reflect the increased number of common shares authorized for repurchase under the amended NCIB. Under the ASPP, Knight's broker may repurchase common shares that it would ordinarily not be permitted to due to regulatory restrictions or self-imposed blackout periods.

About Knight Therapeutics Inc.

Knight Therapeutics, headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. The company's common shares trade on the Toronto Stock Exchange under the symbol GUD.

We seek Safe Harbor.